WO2016070834A1 - 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 - Google Patents

含有细胞周期蛋白抑制剂的药物制剂及其制备方法 Download PDF

Info

Publication number
WO2016070834A1
WO2016070834A1 PCT/CN2015/093953 CN2015093953W WO2016070834A1 WO 2016070834 A1 WO2016070834 A1 WO 2016070834A1 CN 2015093953 W CN2015093953 W CN 2015093953W WO 2016070834 A1 WO2016070834 A1 WO 2016070834A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
compound
prescription
optionally
formula
Prior art date
Application number
PCT/CN2015/093953
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
曾金
王瑞军
王小雷
Original Assignee
江苏豪森药业集团有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏豪森药业集团有限公司 filed Critical 江苏豪森药业集团有限公司
Priority to US15/524,394 priority Critical patent/US20180280392A1/en
Priority to EP15857367.5A priority patent/EP3216450B1/en
Priority to CN201580043546.8A priority patent/CN106794183B/zh
Priority to JP2017521077A priority patent/JP6682739B2/ja
Publication of WO2016070834A1 publication Critical patent/WO2016070834A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention belongs to the field of pharmaceutical preparations, and in particular relates to a pharmaceutical preparation for a cyclin inhibitor and a preparation method thereof.
  • Cyclin-dependent kinase has 13 members, all of which belong to the serine/threonine protein kinase family. It is dependent on cyclin binding, promotes cell cycle phase transition, initiates DNA synthesis, and regulates cell transcription. And other key features.
  • CDKs The critical role of CDKs in the proliferation and death of all cells, including healthy and tumor cells, is that it is difficult for a broad spectrum of CDK inhibitors, especially for patients who have not been genetically screened, to exhibit a higher therapeutic window.
  • the dose is too toxic and too small to be effective. Therefore, it is particularly important to selectively suppress part of the CDK.
  • CDK subtypes have relatively similar chemical structures, how to increase the selectivity of CDK inhibitors is another challenge.
  • CDK4/6 as an anti-tumor target is that: 1 CDK4/6 inhibitor does not exhibit cytotoxicity of "pan-CDK inhibitor", such as myelosuppression and intestinal response; 2 cell cyclin D levels are elevated or P161NK4a is lost Live, can increase the sensitivity of cells to drugs, tumor cells have the above phenomenon relative to normal cells, so the drug targeting is increased to some extent.
  • the compound of formula I is a targeted CDK4/6 inhibitor that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), restores cell cycle control, and blocks tumor cell proliferation. Its effect on MDA-MB-435 breast cancer cells can effectively reduce the phosphorylation of Rb at Ser780 and Ser795, IC50 is 66nM and 63nM, respectively.
  • Breast cancer is one of the most common malignant tumors in women. It has a high incidence and is invasive, but the course of disease is slow. According to data released by the International Agency for Research on Cancer, there were approximately 1.67 million new cases worldwide in 2012, accounting for 25% of all cancers. According to the National Cancer Center's Epidemiological Survey and Final Results (SEER), the estimated prevalence of breast cancer in the United States in 2013 was 123.8 per 100,000. The incidence of breast cancer among women in the Asian population from 2005 to 2009 was 94.5 per 100,000. There is no official data in China. It is estimated that 60% to 70% of breast cancer patients in China have positive estrogen or progesterone receptors. The incidence of estrogen receptor-positive breast cancer in China from 2005 to 2009 is estimated to be 56.7 ⁇ 66.15/10. Ten thousand people. Thomson predicts that sales will increase significantly after the launch of the product, and sales in 2019 will reach $2.027 billion.
  • a pharmaceutical composition comprising a compound of formula I or a salt thereof, and a pharmaceutically acceptable excipient, including a hydrochloride salt, an isethionate, and a pharmaceutically acceptable excipient.
  • the compound of formula I comprises from 10% to 80%, preferably from 15% to 60%, more preferably from 20% to 40% by weight of the composition.
  • the composition comprises a compound of the formula I or a salt thereof and an excipient, the excipient comprising one or more of a disintegrant, a diluent, a binder, a surfactant, a lubricant, preferably
  • the weight of each component is as follows:
  • composition may further comprise a flavoring agent, a coloring agent or a coating material, and most preferably, the sum of the weight percentages of the above components is 100%.
  • the weight percentage of each component is as follows:
  • composition may further comprise a flavoring agent, a coloring agent or a coating material, and most preferably, the sum of the weight percentages of the above components is 100%.
  • the weight percentage of each component is as follows:
  • the diluent is selected from at least one of starch, icing sugar, dextrin, lactose, pregelatinized starch, calcium hydrogen phosphate, calcium sulfate, calcium carbonate, mannitol, sorbitol, and microcrystalline cellulose, further Preferably, the diluent is selected from at least one of lactose, microcrystalline cellulose, starch or mannitol, and more preferably, the diluent is selected from the group consisting of lactose and microcrystalline cellulose.
  • the weight ratio of the lactose to the microcrystalline cellulose is from 1:2 to 2:1, preferably 1:1.
  • the binder is selected from at least one of starch syrup, hypromellose, hydroxypropyl cellulose, povidone, methyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, and the like.
  • the diluent is selected from at least one of hydroxypropyl cellulose or povidone.
  • the disintegrant is selected from at least one of croscarmellose sodium, sodium carboxymethyl starch, crospovidone, dry starch, low-substituted hydroxypropylcellulose, and more preferably, The disintegrant is selected from at least one of crospovidone, sodium carboxymethyl starch, and croscarmellose sodium.
  • the lubricant is selected from at least one of magnesium stearate, stearic acid, sodium stearyl fumarate, glyceryl behenate, colloidal silica, talc, and silica.
  • the lubricant is selected from at least one of stearic acid, glyceryl behenate, and colloidal silica.
  • the surfactant is sodium lauryl sulfate, Tween 80 and poloxamer. More preferably, the surfactant is sodium lauryl sulfate.
  • the present invention provides a process for the preparation of a compound of formula (I) or a salt thereof, which comprises a process such as wet granulation, dry granulation, direct mixing, and the like, and the dosage form includes tablets and capsules.
  • composition is completed by wet granulation, the method comprising the steps of:
  • step (3) drying the particles of step (2) in a fluidized bed dryer or drying oven;
  • step (3) optionally, drying and sieving the dried granules of step (3);
  • step (4) mixing the dried granules of step (4) with the remaining excipients to obtain a final mixture
  • step (6) optionally, filling the mixture of the above step (5) by a suitable capsule filling machine to prepare a capsule;
  • step (7) optionally, by compressing the mixture of the above step (5) on a suitable tablet press, and compressing the sheet to obtain a core;
  • the core of the step (7) is film-coated with a film coating.
  • the composition is accomplished by dry granulation, the method comprising the steps of:
  • step (2) compacting the mixture of step (1) in a suitable roller press
  • step (4) optionally, filling the mixture of the above step (4) by a suitable capsule filling machine to prepare a capsule;
  • step (6) optionally, by compressing the mixture of the above step (4) on a suitable tablet press, and compressing the sheet to obtain a core;
  • the core of step (6) is film coated with a film coating.
  • the present invention provides a stable, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H suitable for medical applications.
  • a pharmaceutical preparation of pyrido[2,3-d]pyrimidin-7-one and a salt which has excellent dissolution behavior and good stability, meets the requirements of clinical application, and enables the active ingredient to achieve good in vivo bioavailability degree.
  • Prescription 1 Prescription 2
  • Prescription 3 Prescription 4
  • Prescription 5 Prescription 6
  • Prescription 7 Prescription 8 10min 35 40 32 27 twenty two 42 41 37 15min 62 66 68 56 55 66 69 65 30min 78 82 77 70 73 79 82 79 45min 89 91 93 83 80 87 89 83 60min 95 96 98 88 91 99 96 95
  • Prescription 9 Prescription 10
  • Prescription 11 Prescription 12
  • Compound of formula I 75 75 100 125 Microcrystalline cellulose 38.7 10.8 93.9 117.3 lactose 54.3 18.8 49.7 65.7 Hydroxypropyl cellulose / / / 17.5
  • Povidone 10.5 3.5 14 / Carboxymethyl starch sodium / 10.5 14 17.5
  • the above 1000 tablets of the formula I and the excipients other than magnesium stearate are mixed into a hopper mixer, pressed into a ribbon by a roller press, the ribbon is broken into granules, and magnesium stearate is added. Total Mix for 10min, control the content, fill the capsule. Or pressed into tablets.
  • Prescription 9 Prescription 10
  • Prescription 12 10min 44 38 35 38 15min 69 63 64 70 30min 76 74 75 81 45min 93 90 89 90 60min 98 98 93 92
  • Prescription 13 Prescription 14
  • Prescription 15 Compound of formula I 75 75 75 75 Microcrystalline cellulose 71.8 / 50 lactose 35.9 25.8 15.7 Hydroxypropyl cellulose 10.5 6.0 9.0 Carboxymethyl starch sodium 10.5 6.0 5.0 Cross-linked povidone / 3.0 4.0 Sodium dodecyl sulfate 2.1 / 2.1 talcum powder 2.1 2.1 2.1 Magnesium stearate 2.1 2.1 2.1 weight 210 120 165
  • Prescription 16 Prescription 17
  • Prescription 18 API 2 125 125 125
  • Microcrystalline cellulose 124.3 64.5 27.1 lactose 62.2 64.6 27.1 Hydroxypropyl cellulose 17.5 8.4 16.8
  • Cross-linked povidone / 14 10.5 Croscone sodium 17.5 / / Magnesium stearate 3.5 3.5 3.5 weight 350 280 210
  • API refers to the hydrochloride or isethionate salt of the compound of formula I.
  • the above 1000 prescription API and other excipients other than magnesium stearate are put into the hopper mixer, and the wetting agent is wetted and granulated.
  • the fluidized bed is dried at 45 ° C for 10 min, 1.0 mm sieve, and hardened.
  • the magnesium oleate was mixed for 10 minutes, the content was controlled, and the capsule was filled. Or pressed into tablets.
  • Prescription 16 Prescription 17
  • Prescription 18 5min 70 73 71 15min 95 92 91 30min 98 97 98
  • Prescription 19 Prescription 20
  • Prescription 21 Prescription 22
  • API 2 75 75
  • Povidone 10.5 10.5 8.25 14
  • Carboxymethyl starch sodium / 10.5 5 14
  • API refers to the hydrochloride salt of the compound of formula I (Note: The above formulation is equally applicable to isethionate, and the inventors have tested that the dissolution effect is very close to that of the hydrochloride as an API).
  • the above 1000 prescription API and other excipients except magnesium stearate are put into a hopper mixer, and pressed into a ribbon by a roller press, the ribbon is broken into granules, and magnesium stearate is mixed. 10min, medium control content, filling capsules. Or pressed into tablets.
  • Prescription 19 Prescription 20
  • Prescription 21 Prescription 22 5min 76 70 68 69 15min 99 94 97 91 30min 98 99 99 97
  • Prescription 23 Prescription 24 Prescription 25 API 2 75 100 125 Microcrystalline cellulose 37.3 49.7 62.2 lactose 74.6 99.5 124.3
  • API refers to the hydrochloride salt of the compound of formula I (Note: The above formulation is equally applicable to isethionate, and the inventors have tested that the dissolution effect is very close to that of the hydrochloride as an API).
  • the above 1000 prescription API and excipients were mixed into a hopper mixer, and the content was controlled, and the capsule was filled. Or pressed into a plain tablet, coated, controlled coating weight gain 3%.
  • Prescription 23 Prescription 24 Prescription 25 5min 62 60 59 15min 90 90 94 30min 97 95 99
  • the compound of formula I corresponds to 96 mg of the compound of the formula I isethionate, and other specifications correspond to the conversion.
  • Prescription 26-28 1000 tablets of prescription API and excipients are mixed into the hopper mixer, medium-controlled content, filled capsules.
  • Prescription 29-30 after mixing, directly pressed into a plain tablet, coated, and controlled to increase the weight of the coating by 3%.
  • Prescription 26 Prescription 27
  • Prescription 28 Prescription 29
  • Prescription 30 5min 40 60 82 85
  • 40 15min 82 85 95 95 73
  • 30min 97 100 103 98 99
  • Prescription 31 Prescription 32
  • Prescription 33 Prescription 34
  • Compound of formula I 75 100 100 125 125 Microcrystalline cellulose 86.7 77.1 154.1 144.5 56.3 lactose 86.7 154.1 77.1 144.5 232.7 Carboxymethyl starch sodium 13.5 18 18 22.5 22.5 Colloidal silica 5.4 7.2 7.2 9.0 9.0 Magnesium stearate 2.7 3.6 3.6 4.5 4.5 weight 270 360 360 450 450
  • Prescription 31-32 1000 tablets of prescription API and excipients are mixed into the hopper mixer, medium-controlled content, filled with capsules.
  • Prescription 33-34 after mixing, directly pressed into a plain tablet, coated, and controlled to increase the weight of the coating by 3%.
  • Formula 35 mixing the compound of the formula I and other excipients other than magnesium stearate into a hopper mixer, pressing into a ribbon by a roller press, crushing the ribbon into granules, and adding magnesium stearate to the mixture. 10 min, medium control content, pressed into tablets, coated, controlled coating weight gain 3%.
  • Prescription 31 Prescription 32
  • Prescription 33 Prescription 34
  • Prescription 35 5min 85 77 76 83 70 15min 94 85 91 95 85 30min 98 100 97 99 99
  • Example 8 The capsule prepared in Example 8 was placed in a commercially available package at 40 ° C ⁇ 2 ° C and a relative humidity of 75% ⁇ 5% for 6 months. The test results are shown in Table 1.
  • Prescription 36 Prescription 37
  • Prescription 38 Prescription 39
  • Prescription 40 Prescription 41 Salts of compounds of formula I 1 81 81 81 160 160 160
  • Microcrystalline cellulose 101 67.5 135 100 56.5 33 lactose 101.5 135 67.5 37.5 56.5 66 starch / / / / / / Hydroxypropyl cellulose / / / / 17.5 17.5
  • the compound of the formula I and the external excipient of the lubricant are subjected to wet granulation, dried, and then granulated, and the lubricant is added for 10 minutes, and the content is controlled.
  • Prescription 36 Prescription 37
  • Prescription 38 Prescription 39
  • Prescription 40 Prescription 41 5min 85 79 77 65 56 50 15min 95 89 90 79 80 76 30min 102 96 97 94 93 94

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/CN2015/093953 2014-11-07 2015-11-06 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 WO2016070834A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US15/524,394 US20180280392A1 (en) 2014-11-07 2015-11-06 Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof
EP15857367.5A EP3216450B1 (en) 2014-11-07 2015-11-06 Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof
CN201580043546.8A CN106794183B (zh) 2014-11-07 2015-11-06 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
JP2017521077A JP6682739B2 (ja) 2014-11-07 2015-11-06 サイクリン阻害剤を含有する医薬製剤およびその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410623810.2A CN105616418A (zh) 2014-11-07 2014-11-07 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
CN201410623810.2 2014-11-07

Publications (1)

Publication Number Publication Date
WO2016070834A1 true WO2016070834A1 (zh) 2016-05-12

Family

ID=55908611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/093953 WO2016070834A1 (zh) 2014-11-07 2015-11-06 含有细胞周期蛋白抑制剂的药物制剂及其制备方法

Country Status (6)

Country Link
US (1) US20180280392A1 (ja)
EP (1) EP3216450B1 (ja)
JP (1) JP6682739B2 (ja)
CN (2) CN105616418A (ja)
TW (1) TWI704918B (ja)
WO (1) WO2016070834A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314148A (zh) * 2019-05-07 2019-10-11 安徽金太阳生化药业有限公司 一种磷酸氢钙片的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN117298115A (zh) * 2022-11-18 2023-12-29 轩竹生物科技股份有限公司 CDKs抑制剂的药物组合物及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001857A (zh) * 2002-01-22 2007-07-18 沃尼尔·朗伯有限责任公司 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮
CN104892604A (zh) * 2015-06-19 2015-09-09 北京康立生医药技术开发有限公司 一种新型的cdk4抑制剂的合成方法
CN105213322A (zh) * 2015-10-30 2016-01-06 南京正大天晴制药有限公司 一种干法制粒工艺制备的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
EP1648889B1 (en) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
WO2008057267A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
DK2958916T3 (en) * 2013-02-21 2018-11-12 Pfizer Solid forms of a selective CDK4 / 6 inhibitor
EP3186252A1 (en) * 2014-08-28 2017-07-05 ratiopharm GmbH Method of producing palbociclib and pharmaceutical compositions comprising the same
KR102068423B1 (ko) * 2015-06-04 2020-01-20 화이자 인코포레이티드 팔보시클립의 고체 투여 형태

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001857A (zh) * 2002-01-22 2007-07-18 沃尼尔·朗伯有限责任公司 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮
CN104892604A (zh) * 2015-06-19 2015-09-09 北京康立生医药技术开发有限公司 一种新型的cdk4抑制剂的合成方法
CN105213322A (zh) * 2015-10-30 2016-01-06 南京正大天晴制药有限公司 一种干法制粒工艺制备的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3216450A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314148A (zh) * 2019-05-07 2019-10-11 安徽金太阳生化药业有限公司 一种磷酸氢钙片的制备方法

Also Published As

Publication number Publication date
EP3216450A4 (en) 2018-06-13
CN106794183A (zh) 2017-05-31
CN106794183B (zh) 2021-06-18
EP3216450B1 (en) 2021-09-22
JP2017532347A (ja) 2017-11-02
EP3216450A8 (en) 2018-02-07
US20180280392A1 (en) 2018-10-04
TW201617082A (zh) 2016-05-16
TWI704918B (zh) 2020-09-21
EP3216450A1 (en) 2017-09-13
JP6682739B2 (ja) 2020-04-15
CN105616418A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
WO2016070834A1 (zh) 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
TWI727935B (zh) 含有細胞週期蛋白抑制劑固體分散體的醫藥組成物及其製備方法
US20210154194A1 (en) Ceritinib Formulation
WO2018108157A1 (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
CN104523695A (zh) 一种治疗过度增生性疾病的药物组合物
CN104840960A (zh) 抗糖尿病的药物组合物及其制备方法
NZ760233A (en) Compositions and methods for treatment of abnormal cell growth
CN108125918A (zh) 依维莫司药物组合物
CN107913254A (zh) 一种替格瑞洛分散片及其制备方法
CN114028400A (zh) 一种含有细胞周期蛋白激酶抑制剂的药物组合物及其制备方法
CN115671061A (zh) 一种利格列汀片及其制备方法
CN114831993A (zh) 含有wee1抑制剂的药物制剂组合物及其制备方法
CN113350350A (zh) 一种含有盐酸培唑帕尼的药物组合物的制备方法
WO2024104448A1 (zh) CDKs抑制剂的药物组合物及制备方法
CN115006400A (zh) 一种含有哌柏西利的药物组合物及其制备方法
CN117599009A (zh) 一种卡左双多巴三层片及其制备方法
CN114832112A (zh) 含有alk激酶抑制剂的药物制剂组合物及其制备方法
CN108066347A (zh) 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
CN103860550A (zh) 左旋多巴/卡比多巴/罗匹尼罗药物制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15857367

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017521077

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015857367

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15524394

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE